Articles, systems, and methods related to the separation of at least a first species from at least a second species using nanoporous membranes are generally described.
The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
This invention provides compositions, reagents, methods, and kits for producing derivatized RNA molecules, particular mRNA molecules encoding a polypeptide and in particular a therapeutic protein, derivatized by linkage to a peptide, aptamer, synthetic DNA or RNA oligonucleotide or molecular probe, capable of targeting the derivatized RNA molecules to a particular subcellular location in a target cell.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
Described is a device having three-dimensional (3D) integration of a DRAM die and processor ASIC. Such an integrated device achieves much higher memory bandwidth and low memory access power consumption than prior art devices while still retaining the high capacity and low cost of DRAMs. The devices and techniques described herein can result in much higher computational throughput, higher power efficiency, and lower cost per throughput than conventional processors while still providing the high memory capacity necessary to be able to work on large problems.
H01L 25/04 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant tous d'un type prévu dans une seule des sous-classes , , , , ou , p. ex. ensembles de diodes redresseuses les dispositifs n'ayant pas de conteneurs séparés
H10B 80/00 - Ensembles de plusieurs dispositifs comprenant au moins un dispositif de mémoire couvert par la présente sous-classe
This disclosure provides compositions and methods for treating subjects having cancer. It is based, in part, on an improved ability to modulate and orchestrate the activity of different cytokines, and thereby mount an effective immune response at a primary tumor site (i.e., a primary site of injection, that may also be but need not be the primary site of cancer development in the subject) but also at distal tumor sites (i.e., metastatic lesions). Provided herein are methods that employ localized administration regimens for cytokine fusion proteins that target the universal leukocyte receptor CD45. The cytokine fusion proteins comprise the cytokine of interest, namely IL-12 or IL-15, fused to a CD45-specific binding moiety. The Examples demonstrate that such immunocytokine fusions can be used to achieve a highly efficacious and non-toxic cytokine therapy that elicits complete responses at injected lesions as well as distal un-injected lesions.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Tissue access systems and methods for the minimally invasive delivery of hardware into tissues and organs are provided. The systems include an applicator charged with a hardware payload having a programmable trajectory projection cap. The trajectory projection cap has internal channels configured to redirect hardware subcomponents in a predetermined direction and at a predetermined angle to deliver the hardware subcomponents to a specific position in tissue, to pass through specific tissue, or to avoid specific tissue.
Described in certain example embodiments herein are engineered delivery vesicle generations systems capable of producing engineered delivery vesicles containing two or more different retroelement polypeptides. Also described herein are methods of making and using the engineered delivery vesicles, such as to deliver one or more cargoes.
A61K 9/1272 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères comprenant des agents tensioactifs non phosphatidyliques comme substances formant des bicouches, p. ex. lipides cationiques ou liposomes non phosphatidyliques enduits de ou greffés avec des polymères
Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
10.
PARTICLES WITH COVALENTLY LIPID-BOUND IMMUNOSTIMULATORY AGENTS
Disclosed herein are particles, compositions, methods, and kits of particles comprising immunostimulatory agents that can be useful in the treatment or prevention of diseases, such as cancer.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A system and method for interactive visualization of knowledge provided by large language models (LLMs) is disclosed. The system advantageously organizes LLM responses into an interactive knowledge graph visualization. Additionally, the system enables the user to interactively expand a knowledge graph by further prompting the LLM to provide additional responses that include additional knowledge. When applied to the task of design ideation, the interactive knowledge graph visualization helps to mitigate design fixation and enhances the overall efficiency, quality, quantity, and depth of concepts in the ideation process.
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
An initial protein sequence is identified and varied to generate a plurality of variants. An activity of the plurality of protein sequences is measured quantitatively. Each of the plurality of protein sequences is provided as an input to a large language model (LLM) to generate a corresponding plurality of embeddings in a latent space. A subset of the plurality of embeddings is used to train a top layer model. The plurality of embeddings are provided as inputs to the top layer model to generate outputs representing predictions of the activity of the plurality of protein sequences. A subset of the plurality of protein sequences is selected based on the top layer model outputs. The method repeats, with the selected subset of the plurality of protein sequences playing the role of the initial protein sequence in the initial iteration, until some termination criterion is satisfied.
Described is a method for reducing parasitic ZZ interactions using third-order dispersive interactions and its implementation in superconducting qubits. In one example embodiment, a system comprises a first fluxonium qubit; a second fluxonium qubit; and a resonant circuit coupled to both the first fluxonium qubit and the second fluxonium qubit according to respective coupling strengths, wherein interactions between the resonant circuit and the first and second qubits alters at least one energy levels of computational states of the system to thereby reduce an always-on ZZ interaction.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
G01R 33/035 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs supraconducteurs
15.
PARTICLES WITH COVALENTLY LIPID-BOUND IMMUNOSTIMULATORY AGENTS
Disclosed herein arc particles, compositions, methods, and kits of particles comprising immunostimulatory agents that can be useful in the treatment or prevention of diseases, such as cancer.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
in situin situin situ after injection into the tissue of the subject, wherein molecules of the drug are released via surface erosion from the implant. The implant may include a packing efficiency above 97%, and the drug may comprise microcrystals. The composition may be injectable by hand using a needle with a gauge of in a range of 16-30G, wherein the injection by hand includes less than 64 N of force at a 6 mL/minute injection rate.
A device configured to be implanted in a subject includes a sensing module, a therapeutic module, and a battery. The sensing module includes at least two of an accelerometer, an electrocardiogram (ECG) sensor, a photoplethysmogram (PPG) sensor, and a temperature sensor. The therapeutic module includes a drug reservoir and a reciprocating pump. The battery powers the sensing module and the therapeutic module. The sensing module is configured to detect a biological event in the subject and, upon detection of the biological event, send a signal to the therapeutic module. The therapeutic module is configured to receive the signal from the sensing module and, upon receiving the signal, administer a drug to the subject from the drug reservoir via the pump.
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
18.
COMPOSITIONS AND METHODS FOR IMPROVED TISSUE REGENERATION
Methods, compositions, and kits of parts for preventing or reducing wound contraction. Methods that may include reducing or eliminating a contractile force applied at a tissue wound site by a continuous myofibroblast network. Compositions may include a biocompatible liquid, and a myofibroblast receptor binding agent dispersed in the biocompatible liquid. Kits of parts may include a reservoir and an applicator, such as a nozzle, needle, brush, dropper, or roller.
Disclosed herein are systems and techniques for seamless and scalable piezoresistive matrix-based intelligent textile development using digital flat-bed and circular knitting machines. Disclosed embodiments allow for combining and customizing functional conductive and polyester and spandex yarns, thus allowing for designing the aesthetics and architecting and engineering both the electrical and mechanical properties of the pressure sensing textile. In addition, by incorporating a melting fiber, disclosed embodiments allow for shaping and personalizing a three-dimensional piezoresistive fabric structure that can conform to the human body through thermoforming principles.
D04B 15/66 - Dispositifs pour déterminer ou commander les dessins
D04B 1/16 - Autres tricots ou articles caractérisés principalement par l'emploi de matières spéciales pour le fil fils synthétiques
D04B 1/24 - Procédés de tricotage trame pour la production de tricots ou d'articles ne dépendant pas de l'emploi de machines spécialesTricots ou articles définis par de tels procédés spécialement conçus pour le tricotage d'articles de configuration particulière articles vestimentaires
G06F 3/041 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction
G06F 3/045 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction utilisant des éléments résistifs, p. ex. une seule surface uniforme ou deux surfaces parallèles mises en contact
Disclosed embodiments may include systems and methods of a permanent magnet (PM) hybrid core inductor and fabrication methods thereof. The permanent magnet hybrid core may include a first set of members comprising a soft magnetic material, the first set of members forming a first gap between two end faces of the first set of members, and a second set of members comprising a permanent magnetic material and located adjacent to the first set of members, wherein the second set of members provides at least a partially parallel path to the first set of members for flow of magnetic flux lines. Some embodiments may include an inductor comprising the permanent magnet hybrid core, or a power conversion circuit including a switched capacitor circuit and a switching regulator, the switching regulator including an inductance, the inductance comprising an electrical conductor wound around a permanent magnet hybrid core.
The present disclosure provides molecular time capsules (MTCs) that are selfassembled protein capsules for high-fidelity RNA capture and storage inside cytoplasm from living cells.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 14/025 - Papovaviridae, p. ex. virus du papillome, virus du polyome, SV40, virus BK, virus JC
C07K 14/15 - Rétroviridae, p. ex. virus de la leucémie bovine, virus de la leucémie féline, virus de la leucémie lymphoïde des lymphocytes-T humains
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
22.
SITE-SELECTIVE CONJUGATION OF A PHARMACEUTICAL AGENT TO AN ANTIBODY USING AN AFFINITY PEPTIDE
The present disclosure provides site- selective conjugation of a pharmaceutical agent to an antibody using an affinity peptide. The antibody-pharmaceutical agent conjugates may be useful in treating, preventing, or diagnosing diseases in subjects.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
This disclosure relates to new multi-modal sensing array architectures that can sense normal and shear forces. Examples include resistive sensing arrays that are used to measure changes in the environment and manufacturing processes to produce multi-modal sensing arrays in a highly-automated and inexpensive fashion. Specifically, a manufacturing process includes a cutting operation and sewing/embroidery technique that creates a fully automated process to produce a resistive sensing array. The new manufacturing process enables the reduction of processing time and materials to produce a functioning sensor without limiting the designs space of achievable sensor geometries. Also presented are sensor reading methodologies for high-speed reading that are capable of sensing vibrations and a wide range of forces. Examples include the use of the new sensor arrays in wearable devices.
G01L 1/20 - Mesure des forces ou des contraintes, en général en mesurant les variations de la résistance ohmique des matériaux solides ou des fluides conducteurs de l'électricitéMesure des forces ou des contraintes, en général en faisant usage des cellules électrocinétiques, c.-à-d. des cellules contenant un liquide, dans lesquelles un potentiel électrique est produit ou modifié par l'application d'une contrainte
G06F 3/045 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction utilisant des éléments résistifs, p. ex. une seule surface uniforme ou deux surfaces parallèles mises en contact
24.
METHODS AND APPARATUS FOR GENERATING COHERENT LIGHT AT NEW FREQUENCIES VIA TIME VARYING LASING
A time varying laser which can operate by taking advantage of transitions between time varying quasi-energy levels which are present in the driven system is disclosed. This can allow for laser operation at frequencies which are new, compared to the operation of the laser in absence of time-modulation. It can also allow for a novel mode of operation in which the system provides gain at multiple frequencies simultaneously, in a coherent fashion which is fundamentally different from multi-mode behavior in conventional lasers. Additionally, in systems with sufficiently strong modulation, these principles can lead to lasers which produce gain even in the thermodynamic ground state of the system, leading to a new form of lasing without inversion (LWI). In addition, these techniques have the potential to be used to create lasers at high frequencies (UV-Xray) which have been difficult to achieve via conventional laser mechanisms.
Aspects of the present disclosure relate to an article. In some embodiments, the article is a gastric retention device or a gastrointestinal device. In some embodiments, the article comprises one or more reservoirs comprising a therapeutic payload. In some embodiments, the article comprises one or more triggerable release mechanisms. In some embodiments, the triggerable release mechanism comprises a metal seal. In some embodiments, release of the therapeutic payload is accomplished via electrochemical dissolution of the metal seal. Other aspects of the disclosure relate to methods for delivering a drug using the drug delivery articles disclosed herein.
26.
PROGRAMMABLE LIPID NANOPARTICLE DELIVERY VIA CORONA PROTEIN ENGINEERING
Disclosed are compositions comprising a lipid nanoparticle and a modified biomolecular corona. In some embodiments, the modified biomolecular corona comprises a fused cell-specific binding domain. In some embodiments, the modified biomolecular corona protein has been additionally modified such that it does not bind substantially to its natural receptor. In some embodiments, the fused cell-specific binding domain binds to a target cell.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A terahertz imaging system is disclosed. The terahertz imaging system includes a terahertz antenna array, made up of a plurality of antenna elements. Each antenna element includes a patch antenna, a one bit phase shifter, and a plurality of storage elements. The storage elements are used to store a plurality of phase states that are supplied to the one bit phase shifter. The one bit phase shifter is configured to either shift the phase of the incoming signal by 90 or 270, depending on the value of the phase state. The one bit phase shifter is also bidirectional, allowing it to phase shift transmitted signals and reflected signals. A plurality of these antenna elements are disposed in a semiconductor device, where the top metal layer is exposed. This top metal layer is used to create the patch antennas.
The exponential growth in deep learning models is challenging existing computing hardware. Optical neural networks (ONNs) accelerate machine learning tasks with potentially ultrahigh bandwidth and nearly no loss in data movement. Scaling up ONNs involves improving scalability, energy efficiency, compute density, and inline nonlinearity. However, realizing all these criteria remains an unsolved challenge. Here, we demonstrate a three-dimensional spatial time-multiplexed ONN architecture based on dense arrays of microscale vertical cavity surface emitting lasers (VCSELs). The VCSELs, coherently injection-locked to a leader laser, operate at gigahertz data rates with a 7T-phase-shift voltage on the 10-millivolt level. Optical nonlinearity is incorporated into the ONN with no added energy cost using coherent detection of optical interference between VCSELs.
G06N 3/067 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens optiques
29.
DEVICES, SYSTEMS, AND METHODS INCLUDING MICRO- OR NANO- CANTILEVER STRUCTURES
A cantilever may include a first dielectric layer that has a first intrinsic stress and a second dielectric layer overlying the first dielectric layer that has a second intrinsic stress that is different than the first intrinsic stress. The difference between the first and second intrinsic stresses may cause the cantilever to curve. A second dielectric layer can comprise a plurality of crossbars oriented at an angle relative to a length of the cantilever to reduce curvature in a width direction of the cantilever. The second dielectric layer can be patterned with a waveguide. The cantilever may be piezoelectrically actuated.
H10N 30/20 - Dispositifs piézo-électriques ou électrostrictifs à entrée électrique et sortie mécanique, p. ex. fonctionnant comme actionneurs ou comme vibrateurs
G02F 1/295 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de la position ou de la direction des rayons lumineux, c.-à-d. déflexion dans une structure de guide d'ondes optique
H01L 25/16 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant de types couverts par plusieurs des sous-classes , , , , ou , p. ex. circuit hybrides
30.
LAYER TRANSFER USING PATTERNED MASKS AND RELATED SYSTEMS
Methods for growing an epitaxial layer are described herein. In some embodiments, an epitaxial layer is grown over a structure comprising a crystalline substrate and a mask. The mask can be patterned with a plurality of elongated domains that help may facilitate the growth of the epitaxial layer with a reduced number of defects on the crystalline substrate. The mask may also facilitate the separation of the epitaxial layer from the crystalline substrate to form a separated epitaxial layer that is freestanding. In some embodiments, the method for growing an epitaxial layer may allow for heteroepitaxy of compound semiconductors on elemental substrates with a reduced number of defects despite polarity and/or lattice mismatches.
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues of organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provide dare methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A01K 67/0275 - Vertébrés modifiés génétiquement, p. ex. transgéniques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Described in various embodiments herein are tiled amplification nucleic acid detection systems and uses thereof. In some embodiments, the nucleic acids amplified and detected are cell free DNA (cfDNA).
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes
33.
APPARATUS FOR LASER-DRIVEN INERTIAL CONFINEMENT AND TRITIUM PRODUCTION
An apparatus and method produce, from a Gaussian laser pulse, a sequence of laser rings having a spatiotemporal configuration such that impingement of the laser rings on a surface of a nuclear material in a target assembly produces constructively interfering shock waves that converge on a focal region of the nuclear material, thereby producing sufficient pressures and temperatures to form tritium in the focal region. The temporal and/or spatial intervals between the concentric pulsed laser rings are adjusted to substantially match propagation times of impingement from one ring to the next in a shock propagation layer of the target assembly. A second laser or neutron tube may be used to create a cavitation bubble at the focus. In addition to the shock waves generated in the plane of the surface, through-plane shock waves can be generated to increase the overall shock pressure.
G21G 1/12 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs à l'extérieur des réacteurs nucléaires ou des accélérateurs de particules par irradiation électromagnétique, p. ex. de rayons gamma ou de rayons X
G21B 1/03 - Réacteurs de fusion thermonucléaire avec confinement inertiel du plasma
G21B 1/13 - Première paroiParoi de couvertureDivertor
G21B 1/19 - Cibles pour la production de réactions de fusion thermonucléaire
G21B 1/23 - Systèmes optiques, p. ex. pour l'irradiation de cibles, pour le chauffage du plasma ou pour le diagnostic du plasma
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
RNA editing tools for use in systems designed to measure RNA in vivo and manipulate specific cell types are disclosed herein. An RNA sensor system comprising a) a single-stranded RNA (ssRNA) sensor comprising a stop codon and a payload; optionally wherein the ssRNA sensor further comprises a normalizing gene; and b) an adenosine deaminase acting on RNA (ADAR) deaminase; wherein the sensor is capable of binding to a ssRNA target to form a double-stranded RNA (dsRNA) duplex that becomes a substrate for the ADAR deaminase; wherein the substrate comprises a mispairing within the stop codon; and wherein the mispairing is editable by the ADAR deaminase, which editing can effectively remove the stop codon so as to enable translation and expression of the payload. A method of quantifying ribonucleic acid (RNA) levels using the RNA sensor system is also disclosed.
C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
36.
SPARSE CLOSED-FORM LIQUID NEURAL ALGORITHMS FOR OUT-OF-DISTRIBUTION GENERALIZATION ON EDGE ROBOTS
According to one aspect, a system includes an autonomous agent and a sparse closed-form network. The autonomous agent has one or more cameras configured to receive images of an environment in which the agent is operating, one or more motors, and a controller configured to command the motors to move the agent with desired velocities. The sparse closed-form network is configured to process the images to determine the desired velocities for navigating the agent to a target.
37.
A NANOPORE SYSTEM AND METHOD FOR DETERMINING PROPERTIES OF NANOPARTICLES
SINGAPORE-MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY CENTRE (Singapour)
NATIONAL UNIVERSITY OF SINGAPORE (Singapour)
Inventeur(s)
Garaj, Slaven
Doyle, Patrick Seamus
Li, Kun
Shah, Arjav
Shikha, Swati
Abrégé
A method and system for determining mechanical properties of nanoparticles. The method comprises the steps of providing an electrically conducting fluid comprising the nanoparticles dispersed therein in a fluidic cell configured with a membrane having a nanopore extending through a thickness of the membrane; applying a voltage across the fluidic cell for effecting a translocation event of at least one of the nanoparticles through the nanopore; monitoring a current across the fluid cell for a period starting before the translocation event and ending after the translocation event to measure a current blocking signal; and determining the mechanical properties of the nanoparticles from the measured current blocking signal; wherein a size of the nanoparticles is larger than a pore size of the nanopore; and wherein an aspect ratio of thickness of the membrane to the pore size of the nanopore is smaller than 1.
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 15/00 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
Reaction schemes involving acids and bases; reactors comprising spatially varying chemical composition gradients (e.g., spatially varying pH gradients), and associated systems and methods, are generally described.
Some aspects of the present disclosure are related to modified electrodes, for example, for use in fuel cells. In some cases, the electrode may comprise a mixed-ionic-electronic-conducting (MIEC) oxide and a basic oxide. In some cases, the basic oxide may alter the electron density of the MIEC oxide and improve its catalytic performance, for example, like the oxygen reduction reaction. For instance, the catalytic performance of a MIEC oxide comprising a perovskite towards the oxygen reduction reaction (ORR) may be improved by using a basic oxide comprising CaO and/or Li2O. Some aspects disclosed herein are directed to methods of preventing or treating chromia or silica poisoning of a MIEC oxide, wherein the method comprises treating the MIEC electrode with a basic oxide infiltrant.
C12P 23/00 - Préparation de composés contenant un cycle cyclohexène comportant une chaîne latérale non saturée d'au moins dix atomes de carbone liés par des doubles liaisons conjuguées, p. ex. carotènes
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
Parameters of a first transformer are accessed, and size dimensions of a second transformer that is to be trained and is larger than the first transformer are received. The parameters of the first transformer are linearly transformed using a combination of a width-growth operator and a depth-growth operator, wherein the linear transformation produces a set of new parameters, the set corresponding to the size dimensions of the second transformer. The second transformer is initialized with the set of new parameters.
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In son embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
The disclosure features compositions, systems, and methods for preparation and use of efficient RNA nuclear export of ribozyme-assisted circular RNA molecules (racRNAs). In embodiments, the methods involve characterizing a cell or tissue using racRNAs.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
G16B 50/30 - Entreposage de donnéesArchitectures informatiques
45.
SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE)
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
Compositions including solid forms of polypeptides such as crystalline antibodies, and related methods, are generally described. The compositions may include carriers such as hydrogels that at least partially encapsulate the solid form of the polypeptides (e.g., crystals, amorphous solids). Encapsulation with certain of the materials described may result in compositions containing relatively high loadings of polypeptides while in some instances retaining structural and functional properties of the polypeptides useful for certain types of administration to subjects (e.g., for prophylactic or therapeutic applications). In some instances, compositions having relatively low dynamic viscosities while having relatively high polypeptide loadings are provided.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure provides methods (referred to herein as "SWITCH-seq"), compositions, kits, and systems for profiling RNA expression in a cell (including, e.g., cells within an intact tissue) in both untargeted and targeted manners. Also provided by the present disclosure are methods for diagnosing a disease or disorder in a subject based on a profile of RNA expression in a cell tissue, or other biological sample. Methods of screening for or testing a candidate agent capable of modulating RNA expression are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder in a subject in need thereof. Oligonucleotides useful for performing the methods described herein are also provided by the present disclosure. Additionally, the present disclosure provides kits comprising any combination of the oligonucleotides described herein.
Pseudomonas aeruginosaP. aeruginosa)P. aeruginosa), which poses significant health threats to humans. From this, Applicants isolated a compound that effectively activated complement immunity to inhibit bacterial growth. Furthermore, Applicants developed a robust testing platform for complement-recruiting compounds, allowing the streamlined assessment of ternary complex formatoon and the efficacy of novel bifunctional molecules for recruiting the complement system and inhibiting bacterial growth. These findings demonstrate the potential of this approach in combating antibiotic-resistant P. aeruginosa infections, with implications for other bacterial pathogens or diseases.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
In some aspects, the present disclosure pertains to methods for the electrochemical production of NH3 from nitrogen gas and a hydrogen-containing molecule in an electrochemical cell that comprises a cathode, an anode and a lithium-ion-containing electrolyte disposed between the cathode and the anode. The electrochemical cell is operated under conditions such that lithium ions in the electrolyte are converted to lithium metal at the cathode, the lithium metal reacting with nitrogen gas to form Li3N, and the Li3N reacting with protons in a proton donor to form NH3, lithium ions and a deprotonated proton donor. Moreover, the proton donor has a Kamlet-Taft alpha parameter (α) greater than 0.7 and a Kamlet-Taft beta parameter (β) greater than 0.5. Other aspects of the present disclosure pertain to systems for electrochemical production of NH3.
The present disclosure provides cyclic silyl ethers of the formula:
The present disclosure provides cyclic silyl ethers of the formula:
The present disclosure provides cyclic silyl ethers of the formula:
and salts thereof. The cyclic silyl ethers may be useful as monomers for preparing polymers. Also described herein are polymers prepared by polymerizing a cyclic silyl ether and optionally one or more additional monomers. The polymers may be degradable (e.g., biodegradable). One or more O—Si bonds of the polymers may be the degradation sites. Also described herein are compositions and kits including the cyclic silyl ethers or polymers; methods of preparing the polymers; and methods of using the polymers, compositions, and kits.
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C08G 61/06 - Composés macromoléculaires contenant uniquement des atomes de carbone dans la chaîne principale de la molécule, p. ex. polyxylylènes uniquement des atomes de carbone aliphatiques préparés par ouverture du cycle des composés carbocycliques
C08L 79/08 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide-acides ou précurseurs similaires de polyimides
The present invention relates to recombinant targeting peptides, compositions comprising said targeting peptides and methods of targeted delivery of therapeutics suitable for the control, improvement and/or treatment of acne. More particularly, the present invention provides engineered targeting peptides that bind specifically to the cell wall of Cutibacterium acnes, capable of providing a homing mechanism for transporting nanoparticles comprising therapeutics to C. acnes. Accordingly, the present invention also provides methods and compositions comprising the recombinant targeting peptides for localized delivery of therapeutics to C. acnes.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
C12N 9/36 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-1, 4 de l'acide N-acétylmuramique avec l'acétylamino-2 déoxy-2-D-glucose, p. ex. lysozyme
Engineered, non-naturally occurring, RNA-targeting Type V Cas polypeptides lacking collateral cleavage activity, compositions thereof, CRISPR-Cas systems thereof, packaging and delivery systems thereof, kits thereof, and methods of use thereof, for modifying target RNA. The Type V Cas polypeptide may be a Cas 12 polypeptide, optionally a Casl2a2 polypeptide. The compositions may comprise the Type V Cas polypeptide and an engineered polypeptide comprising a tetratricopeptide repeat (TPR) domain, a DUF3800 domain and, optionally, a UvrD polypeptide and an additional TPR polypeptide. CRISPR-Cas systems may comprise the Type V Cas polypeptide, or a composition thereof, and one or more guide molecules.
Disclosed herein is a microfluidic 3D cell culture device that supports the housing and swelling of cell culture scaffolding substances without causing damage to the cells and/or cell aggregates cultured therein, optionally wherein the device has an open-top design. The device is configured to comprise networks allowing for perfusion of fluid throughout, and the configuration of the networks is tunable to the biological question being addressed. The open-top design allows for access to the cells, scaffolding substances and fluid, such that the system is amenable to easy experimental manipulation.
A61F 2/94 - Stents conservant leur forme, c.-à-d. non déformables, après mise en place à l’endroit voulu
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires
A respiratory monitoring system with improved detection of oxygen consumption is described. The system uses one or two mixing chambers and samples gases at selective locations for reliable detection of oxygen over extended periods of time with autonomous detection of calibration drift. The system can be used for indirect calorimetry and monitoring health of a subject.
55.
MEDICAL DEVICES AND IMPLEMENTS WITH LIQUID-IMPREGNATED SURFACES
Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.
The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
57.
Self-Configuration and Error Correction in Linear Photonic Circuits
Component errors prevent linear photonic circuits from being scaled to large sizes. These errors can be compensated by programming the components in an order corresponding to nulling operations on a target matrix X through Givens rotations X→T†X, X→XT†. Nulling is implemented on hardware through measurements with feedback, in a way that builds up the target matrix even in the presence of hardware errors. This programming works with unknown errors and without internal sources or detectors in the circuit. Modifying the photonic circuit architecture can reduce the effect of errors still further, in some cases even rendering the hardware asymptotically perfect in the large-size limit. These modifications include adding a third directional coupler or crossing after each Mach-Zehnder interferometer in the circuit and a photonic implementation of the generalized FFT fractal. The configured photonic circuit can be used for machine learning, quantum photonics, prototyping, optical switching/multicast networks, microwave photonics, or signal processing.
The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorder.
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61K 31/14 - Composés d'ammonium quaternaire, p. ex. édrophonium, choline
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
60.
ADHESIVE MATERIAL WITH TRIGGERABLE ON-DEMAND DETACHMENT
An adhesive material that provides fast and robust adhesion on wet surfaces, where the adhesion formed is detachable on-demand. The adhesive material is formed of one or more hydrophilic polymers or copolymers grafted with one or more amine coupling groups via a plurality of cleavable physical bonds and/or cleavable covalent bonds and one or more cross linkers. Application of the adhesive material on a wet surface causes the adhesive material to absorb liquid to thereby swell the adhesive material to form a layer of hydrogel, resulting in the formation of temporary crosslinks followed by covalent crosslinks with the surface. Introducing a triggering agent cleaves the cleavable physical bonds and/or cleavable covalent bonds to allow for non-traumatic detachment of the adhesive material from the surface.
C09J 7/32 - Adhésifs sous forme de films ou de pellicules caractérisés par la composition de l’adhésif activés au contact de l’eau, p. ex. pour papier gommé
A61L 24/00 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie
C09J 129/04 - Alcool polyvinyliqueHomopolymères ou copolymères partiellement hydrolysés d'esters d'alcools non saturés avec des acides carboxyliques saturés
C09J 133/06 - Homopolymères ou copolymères d'esters d'esters ne contenant que du carbone, de l'hydrogène et de l'oxygène, l'atome d'oxygène faisant uniquement partie du radical carboxyle
C09J 133/10 - Homopolymères ou copolymères d'esters de l'acide méthacrylique
C09J 133/26 - Homopolymères ou copolymères de l'acrylamide ou du méthacrylamide
C09J 151/00 - Adhésifs à base de polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carboneAdhésifs à base de dérivés de tels polymères
C09J 175/00 - Adhésifs à base de polyurées ou de polyuréthanesAdhésifs à base de dérivés de tels polymères
Described herein are nanoparticles comprising an LNP core with electrostatically adsorbed anionic polymers layered on the LNP surface. These nanoparticles comprise varying nucleic acid cargos and may further comprise targeting moieties covalently attached to the anionic polymers. Also provided are methods of administering cargo to a subject, methods of treatment, methods of editing a gene, and methods of reducing non-targeted cell uptake of nanoparticles.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
Systems and related methods for assisting a user to achieve postural changes and ambulation are disclosed. An assistance system may safely assist in a user's (e.g., elderly or physically disabled user) postural changes at any desired position without the need of a physical secondary body for assistance. In some embodiments, the assistance system may include front and back bases, each including a drive to help the system maneuver through an environment (e.g., home). The system may include a linkage formed of three or more links, including one link coupled to the front base and a second link coupled to the back base. In some embodiments, at least one of the joints between the links may be passive. The system may also include an actuator to control the pose of the system and safely lock the system at the desired pose to facilitate postural changes and ambulation.
A61G 5/14 - Moyens pour aider à se lever ou à s'asseoir
A61H 3/04 - Appuis à roues pour aider les personnes handicapées à marcher
A61G 5/02 - Fauteuils ou moyens de transport personnels spécialement adaptés pour des personnes handicapées, p. ex. fauteuils roulants propulsés par la personne handicapée
63.
GENERATION OF QUANTUM CONTROL PULSES AND RELATED SYSTEMS
Described is an optimal-control system and method provide an efficient routine for differentiating the most general Unitary, Liouville, or Monte-Carlo Schrödinger equation associated with the control problem of interest.
G06N 10/60 - Algorithmes quantiques, p. ex. fondés sur l'optimisation quantique ou les transformées quantiques de Fourier ou de Hadamard
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
64.
CORYNEBACTERIUM TO TREAT OR LIMIT CUTANEOUS WOUND INFECTION
Methods and compositions for treating a cutaneous wound to treat or limit development of a pathogenic bacterial infection are provided, involving administering to a subject having a cutaneous wound an amount effective of Corynebacteria spp., or a disclosed, composition, to treat or limit development of pathogenic bacterial infection of the wound.
A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6811 - Méthodes de sélection pour la production ou l’élaboration d’oligonucléotides spécifiques cibles ou de molécules de liaison
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
66.
DEFECT CURRENT CONTROL IN HIGH TEMPERATURE SUPERCONDUCTOR STRUCTURES
Described is a high-temperature superconductor (HTS) cable, comprising a plurality of HTS tapes, wherein all or part of a cross-section of at least one of the HTS tapes are removed to reduce the current carrying capacity of the HTS tape. Also described is a method for shaping the current density of a high-temperature superconductor (HTS) cable, wherein the HTS current density is carried by HTS tapes, and wherein the method comprises selective mechanical removal of all or part of the cross section of one or more of HTS tapes.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Green, Alexander
Braff, Dana
Takahashi, Melissa
Pardee, Keith
Collins, James J.
Lambert, Guillaume
Ferrante, Thomas
Abrégé
Methods for detecting the presence of a pathogen infection are described. In particular, this document provides a method of detecting target nucleic acids, such as pathogen-specific RNA, in a biological sample obtained from a subject, where the method comprises using one or more toehold switch sensors and an isothermal amplification step to detect the target nucleic acid. Methods specific for detecting and identify the presence of a virus such as Zika virus are also provided.
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
68.
LOCALIZING, WAKING-UP, AND ESTIMATING DIRECTION OF FEMTO-SATELLITES
Femto-satellites are very small satellites that can be deployed in constellations from a larger mothership satellite for distributed measurement. They are too small to accommodate the GNSS receivers that many satellites use for navigation, but they can be located with an electromagnetic beam from the mothership satellite. The mothership satellite scans this beam across a constellation of femto-satellites. When the beam scans across a particular femto-satellite, the femto-satellite transmits an acknowledgement to the mothership satellite, e.g., by retroreflecting the beam or via a separate radio link. The beam can be modulated with commands for the femto-satellite, such as to make a measurement or transmit previously acquired data, as well with commands for determining the femto-satellite's location, such as a time stamp or beam pointing information. The femto-satellite can determine its location from the information modulated onto the beam or transmit the time stamp to the mothership satellite for localization.
B64G 3/00 - Observation ou poursuite des véhicules astronautiques
B64G 1/10 - Satellites artificielsSystèmes de tels satellitesVéhicules interplanétaires
B64G 1/44 - Aménagements ou adaptations des systèmes fournissant l'énergie utilisant des radiations, p. ex. panneaux solaires déployables
G01S 1/70 - Radiophares ou systèmes de balisage émettant des signaux ayant une ou des caractéristiques pouvant être détectées par des récepteurs non directionnels et définissant des directions, situations ou lignes de position déterminées par rapport aux émetteurs de radiophareRécepteurs travaillant avec ces systèmes utilisant des ondes électromagnétiques autres que les ondes radio
G01S 5/16 - Localisation par coordination de plusieurs déterminations de direction ou de ligne de positionLocalisation par coordination de plusieurs déterminations de distance utilisant des ondes électromagnétiques autres que les ondes radio
G01S 17/74 - Systèmes utilisant la reradiation d'ondes électromagnétiques autres que les ondes radio, p. ex. pour l'identification ami–ennemi
69.
COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E
This disclosure relates to synthetic peptides, peptidomimetics, and complexes of synthetic peptides and peptidomimetics with HLA-E, methods of making such peptides, peptidomimetics, and complexes, and methods of using such peptides, peptidomimetics and complexes for blocking, inhibiting, or preventing the interaction of HLA-E with CD94/NKG2A or activation of CD94/NKG2A by HLA-E. The synthetic peptides, peptidomimetics, and complexes of synthetic peptides and peptidomimetics with HLA-E can further comprise warheads to introduce covalent linkages between the synthetic peptides and peptidomimetics with HLA-E.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A sequence-to-fixed-length transformation is used to process a sequence representation of a molecule structure to yield a fixed-length representation. A transformation of the fixed-length representation yields a prediction of one or more properties of the molecular structure. For example, the molecular structure is a candidate drug and the process described above is part of a screening procedure.
Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more LTR retroelement polypeptides for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more LTR retroelement polypeptides for forming a delivery vesicle may comprise two or more of an LTR retroelement gag protein, a retroelement envelope protein, an LTR retroelement reverse transcriptase, or a combination thereof. The LTR retroelement polypeptide alone, the LTR retroelement envelope protein alone, or both the LTR retroelement-derived polypeptide and LTR retroelement envelope protein may be endogenous.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Systems and methods of controlling a robot are described. In some embodiments, a method includes obtaining an input motion trajectory defining movements of the robot to perform a task and input speech corresponding with descriptions of the task. A control signal is provided to control movement of the robot based on the input motion trajectory to interact with an environment surrounding the robot with an end effector of the robot. Feedback information about the end effector resulting from the control signal is obtained, and output speech is generated by modulating the input speech based on the feedback information about the end effector.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Barrett, Christopher, D.
Yaffe, Michael, B.
Abrégé
Compositions and methods for increasing intrapleural fibrinolysis and inhibiting, treating, and/or preventing pleural space infections and/or hemothorax are disclosed.
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
75.
BULK-MATERIAL BASED FLEXIBLE THERMOELECTRIC GENERATORS FOR HEAT CONCENTRATION AND DISSIPATION
SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
Inventeur(s)
Xu, Qian
Chen, Gang
Liu, Weishu
Deng, Biao
Zhang, Pengxiang
Abrégé
The present disclosure generally relates to high-performance flexible thermoelectric generators (f-TEGs) for heat concentration and dissipation. In some embodiments, the f-TEGs can be incorporated into wearable devices. The f-TEG device can include an f-TEG network of thermoelectric units that include multifunctional thin copper disks that can be used as electrodes, heat concentrators and spreaders, spacers, and flexibility enablers. Each electrode can include a spacer extending therefrom to suppress the heat loss between the hot and the cold sides through conduction and convection across a thermoelectric pillar disposed therebetween. In some embodiments, the f-TEG network can be associated with a fabric to provide good wearability and comfort even in wet thermal environments.
H10N 10/17 - Dispositifs thermoélectriques comportant une jonction de matériaux différents, c.-à-d. dispositifs présentant l'effet Seebeck ou l'effet Peltier fonctionnant exclusivement par les effets Peltier ou Seebeck caractérisés par la structure ou la configuration de la cellule ou du thermocouple constituant le dispositif
76.
RATE OF PENETRATION/DEPTH MONITOR FOR A BOREHOLE FORMED WITH MILLIMETER-WAVE BEAM
Apparatus and methods are described for drilling deep boreholes with millimeter-wave radiation in earthen materials to access deep resources such as geothermal heat. Borehole depth and temperature at the bottom of the borehole can be monitored with probe signals and/or radiative emission from the bottom of the borehole.
E21B 47/135 - Moyens pour la transmission de signaux de mesure ou signaux de commande du puits vers la surface, ou de la surface vers le puits, p. ex. pour la diagraphie pendant le forage par énergie électromagnétique, p. ex. gammes de fréquence radio utilisant des ondes lumineuses, p. ex. ondes infrarouges ou ultraviolettes
E21B 7/15 - Forage thermique, p. ex. forage à la flamme la chaleur étant produite par l'électricité
E21B 45/00 - Mesure du temps de forage ou de la vitesse de pénétration
E21B 47/022 - Détermination de l'inclinaison ou de la direction du trou de forage, p. ex. à l'aide de géomagnétisme
G01S 13/10 - Systèmes pour mesurer la distance uniquement utilisant la transmission de trains discontinus d'ondes modulées par impulsions
G01S 13/32 - Systèmes pour mesurer la distance uniquement utilisant la transmission d'ondes continues, soit modulées en amplitude, en fréquence ou en phase, soit non modulées
77.
INGESTIBLE CHEMICAL ENERGY HARVESTING SYSTEM WITH EXTENDED LIFETIME
A device is configured to be administered via an oral route by a subject. The device includes an anode, a seal disposed on the anode, and a cathode. When exposed to a liquid or a hydrogel, an exposed surface of the anode undergoes galvanic oxidation dissolution to provide DC power to the device. As the exposed surface of the anode undergoes galvanic oxidation dissolution, the seal incrementally detaches from the anode, and a substantially constant surface area of the exposed surface is maintained.
Novel design frameworks for designing electrodialysis (ED) desalination systems for purifying brackish water are provided herein. The design frameworks of the present embodiments include one or more energy management strategies, as well as recirculation-based system architectures. The design frameworks can be independent of each other, or can be used together. In some embodiments, the energy management strategy can include determining a capacity of a battery in communication with an (ED) system and imposing a charge power limit onto the battery to limit the charging rate of the ED system. The energy management strategy can be used in combination with the recirculation-based system architectures to improve efficiency of purification performed by these ED systems. These architectures can include hybrid architectures that operate in continuous flow, but provide a recirculation stream to mix the feed to achieve a desired salinity of the product stream.
C02F 1/469 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par séparation électrochimique, p. ex. par électro-osmose, électrodialyse, électrophorèse
79.
Streptococcus Canis Cas9 as a Genome Engineering Platform with Novel PAM Specificity
A Streptococcus canis Cas9 (ScCas9) ortholog and its engineered variants, possessing novel PAM specificity, is an addition to the family of CRISPR-Cas9 systems. ScCas9 endonuclease is used in complex with guide RNA, consisting of identical non-target-specific sequence to that of the guide RNA SpCas9, for specific recognition and activity on a DNA target immediately upstream of either an “NNGT” or “NNNGT” PAM sequence. A novel DNA-interacting loop domain within ScCas9, and other Cas9 orthologs, such as those from Streptococcus gordonii and Streptococcus angionosis facilitates a divergent PAM sequence from the “NGG” PAM of SpCas9.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
80.
METHODS AND APPARATUS FOR AUTONOMOUS 3D SELF-ASSEMBLY, SPATIAL DOCKING AND RECONFIGURATION
A method for autonomously assembling a plurality of tiles is performed in a microgravity environment. Each tile includes a shell having a first geometrical shape and an arrangement of first magnets and a controller that are supported by the shell. The controller controls operation of the arrangement of first magnets to self-assemble the shell with another tile. The first magnets are controlled to mate with a complementary arrangement of second magnets on the other tile when the complementary arrangement of second magnets floats to within a range of magnetic attractive force of the arrangement of first magnets, with or without the aid of propulsion. The controllers in the tiles detect the status of the magnetic bonds to determine whether each pair of tiles is properly bonded or has a magnetic bond error. When an error is detected, the tiles are controlled to disassemble and reassemble to correct the error.
B64G 1/22 - Parties de véhicules spatiaux ou équipements spécialement destinés à être fixés dans ou sur ces véhicules
G01R 33/038 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des aimants permanents, p. ex. des balances, des dispositifs à torsion
81.
PRE-STRESSED AND CONSTRAINED TRANSFORMABLE MATERIALS
A transformable material and comprising a base material having a natural shape, with a second material disposed on the base material in a particular pattern so as to impose a transformed shape on the base material, the transformed shape being different than the natural shape. More particularly, the base material is a stretchable 2-dimensional material, and is subjected to pre-stressing before and during disposition of the second material, whereupon after release of the stress, the stretchable base material with the disposed second material thereon automatically transform into a predetermined 3-dimensional manufactured shape.
B29C 61/06 - Fabrication de préformes ayant des contraintes internes, p. ex. mémoire plastique
B29C 55/16 - Étirage suivant plusieurs axes suivant deux axes simultanément
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p. ex. de buses de jet
B29K 105/00 - Présentation, forme ou état de la matière moulée
82.
MEASURING REPRESENTATIONAL MOTIONS IN A MEDICAL CONTEXT
A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
G06Q 10/101 - Création collaborative, p. ex. développement conjoint de produits ou de services
G06Q 50/00 - Technologies de l’information et de la communication [TIC] spécialement adaptées à la mise en œuvre des procédés d’affaires d’un secteur particulier d’activité économique, p. ex. aux services d’utilité publique ou au tourisme
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
83.
SYSTEM AND METHOD FOR CO-DELIVERY OF AN AGENT AND AN ON-PATIENT MEDICAL RECORD SYSTEM WITH SPATIAL AND TEMPORAL ROBUSTNESS
A system delivers, to a living subject, a therapeutic dosage of an agent; delivers, to the living subject, an on-patient medical record (OPMR) comprising a two-dimensional array of dots, encoding information about the agent, reads data from the OPMR in the living subject; applies deep learning-based image processing to the read data to generate binary array data; applies error correction to the binary data to correct errors in the binary data, thereby producing error-corrected data; and translates the error-corrected data into an estimate of the information about the agent. The deep learning-based image processing includes applying deep learning-based image binarization to the read data to produce binarized image data, and applying deep learning-based image recognition to the binarized image data to generate the binary data.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61B 17/20 - Instruments, dispositifs ou procédés chirurgicaux pour la vaccination ou le nettoyage de la peau avant la vaccination
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The invention, in some aspects includes methods and systems for expansion microscopy. Methods of the invention permit performance of iterative expansion protocols with the simplicity of one-shot protocols, achieving ~20x expansion of cell cultures and tissues in a single expansion step, and supporting post-expansion staining of biomolecules.
Disclosed herein are capped RNA transcripts comprising one or more modified nucleotides at position +3 or higher with reference to a 5' terminus of the RNA molecule, and methods of making the same. Also provided are compositions comprising one or more of the capped RNA transcripts provided herein, and methods of using said compositions for therapeutic applications.
The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue/cell).
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue/cell).
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07C 233/47 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes carboxyle avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 231/12 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 233/61 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'azote ne faisant pas partie d'un radical nitro, liés aux atomes d'azote du cycle
C07D 243/08 - Composés hétérocycliques contenant des cycles à sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle les atomes d'azote étant en positions 1, 4 non condensés avec d'autres cycles
C07D 295/13 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants liés à la même chaîne carbonée, qui n'est pas interrompue par des cycles carbocycliques à une chaîne acyclique saturée
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
88.
SPLIT-LUCIFERASE REPORTER SYSTEMS, COLOR-CODED BEAD MULTIPLEX CRISPR SYSTEMS, AND METHODS OF USE THEREOF IN CRISPR-CAS BASED DIAGNOSTICS
Cas-cleavable reporter systems, CRISPR-Cas systems thereof, and methods of use thereof in CRISPR-Cas based diagnostics. Cas-cleavable reporter systems may generate a luminescent, fluorescent, or other detectable signal upon Cas-collateral cleavage of one or more reporter system components. CRISPR-Cas systems may comprise a Cas protein having collateral cleavage activity, guide molecules, and the Cas-cleavable reporter system. Cas-cleavable reporter systems may be a split luciferase reporter system, at least one element of which is bound to beads. For multiplexing, CRISPR-Cas systems may comprise a Cas-cleavable quenched reporter system, optionally a Cas-cleavable quenched fluorescent reporter system, a Cas protein having collateral cleavage activity, and target-specific guide molecules attached to color-coded beads. CRISPR-Cas systems may further comprise amplification reagents. Methods may apply said CRISPR-Cas systems to flow cell, well-plate, or other devices, and may measure detectable signals by microscopic, plate reader, or other methods.
Described herein are engineered paraneoplastic Ma protein (PNMA) capable of forming a capsid. In some embodiments, the engineered PNMA proteins comprise one or more modifications that enhance binding or loading of a cargo into the capsid, one or more modifications that modify cell-specificity of the capsid, one or more modifications that enhance intracellular delivery of the capsid, or a combination thereof. Also described herein are delivery systems comprising capsids comprising an engineered PNMA protein and a cargo.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A multi-armed bandit (MAB) problem is obtained and a per-round regret lower bound is determined, wherein a corresponding regret is measured against a benchmark. The multi-armed bandit problem is provided to an algorithm that has a per-round regret that is close to the determined per-round regret lower bound, wherein the algorithm dynamically adapts to changes and discards irrelevant past information by alternating between recently pulled arms and unpulled arms having potential, wherein the alternating comprises updating an estimate of an expected reward of each arm within each epoch and an estimate for an error bound that captures an amount of error contained in the estimate of the expected reward for each arm within each epoch based on the auto-regressive temporal structure with trend components, and restarting the algorithm.
Apparatus and methods for monitoring emissions from a borehole to determine the composition of earthen material removed from the borehole are described. Monitoring can be done in real time as the borehole is being deepened with a millimeter-wave drilling beam. The present technology can monitor in real-time the elemental composition of the earthen materials (e.g., rock, minerals, crystals, metals, etc.) in a borehole created by a directed-energy beam that melts and vaporizes the earthen material materials in its path. Using a continuous emissions monitor (CEM) in combination with directed-energy excavation of a borehole enables rapid surveying of the subsurface for precious and commercial metals.
G01N 21/66 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité électriquement, p. ex. par électroluminescence
E21B 7/15 - Forage thermique, p. ex. forage à la flamme la chaleur étant produite par l'électricité
E21B 49/00 - Test pour déterminer la nature des parois des trous de forageEssais de couchesProcédés ou appareils pour prélever des échantillons du terrain ou de fluides en provenance des puits, spécialement adaptés au forage du sol ou aux puits
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
Optical and electronic processors for calculating second-order and higher-order polynomials are described. A photonic processor can include an optical matrix multiplying unit OMMU that can perform vector-matrix multiplication. A portion of the inputs to the OMMU can be fed forward to combine with outputs from the OMMU when calculating polynomials. The described apparatus can also be used for probabilistic computing and polynomial combinatorial optimization.
G06E 1/04 - Dispositions pour traiter exclusivement des données numériques agissant sur l'ordre ou le contenu des données maniées pour effectuer des calculs en utilisant exclusivement une représentation numérique codée, p. ex. représentation binaire, ternaire, décimale
This disclosure is directed to a targeted delivery vehicle that can deliver a cargo to a cell of interest. The targeted delivery vehicle has a fusogen and a targeting domain which are embedded in a lipid bilayer membrane that forms a vesicle, and a cargo within the vesicle. The disclosure is also directed to methods for targeted delivery of cargo using the targeted delivery vehicle described herein.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
Described herein are systems and techniques for estimating a shape of a structure undergoing dynamic stress. In some embodiments, a method includes: for each of a plurality of nodes distributed along a length of the structure, obtaining, from an accelerometer located at the node, a tilt angle corresponding to an angle between a local axis of the structure and a direction of gravity; calculating, by a microcontroller, vertical displacements between adjacent pairs of the plurality of nodes using the respective tilt angles obtained for the adjacent pairs; and calculating, by the microcontroller, a depth of each of the plurality of nodes relative to a proximal end of the structure by adding the vertical displacements calculated for adjacent pairs of the plurality of nodes between the node and the proximal end of the structure.
G01B 5/18 - Dispositions pour la mesure caractérisées par l'utilisation de techniques mécaniques pour mesurer une profondeur
G01B 5/213 - Dispositions pour la mesure caractérisées par l'utilisation de techniques mécaniques pour mesurer des contours ou des courbes pour mesurer le rayon de courbure
G01B 11/22 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer la profondeur
95.
CELL-TYPE SPECIFIC TARGETING CONTRACTILE INJECTION SYSTEM
The present disclosure relates generally to the field of delivery systems using contractile injection systems (CIS). Specifically disclosed are engineered extracellular CISs (eCISs) that can deliver non-natural protein payloads to non-natural target cells such as human cells. In addition, methods of using the engineered eCISs are also disclosed.
Tissue explants of the gastrointestinal tract are provided. Methods of making and using the tissue explants are also provided, along with substrates designed for the tissue explants described.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
97.
BACKBONE CLEAVABLE POLYMETHACRYLATES VIA THIONOLACTONE COMONOEMERS
The present disclosure provides thionolactones (e.g., compounds of Formula II, and tautomers and salts thereof). The thionolactones may be useful as comonomers to copolymerize with other comonomers, e.g., methacrylates (e.g., MMA) to generate copolymers, e.g., random copolymers. The copolymers may be degradable (e.g., backbone degradable). The copolymers may be useful for waste management or biodegradability.
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/38 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle
C25B 11/04 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par le matériau
H01M 12/06 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire avec une électrode métallique et une électrode à gaz
99.
Utilization Of Halides To Improve Diamond Properties
Described herein is a diamond and diamond products comprising:
a NV0 or SiV0 defect, wherein the NV0 or SiV0 defect comprises a nitrogen atom or silicon atom replacing a carbon atom in the diamond and a neutral vacancy replacing a carbon atom adjacent to the nitrogen atom or silicon atom in the diamond;
a NV− or SiV− defect, wherein the NV− or SiV− defect comprises a nitrogen atom or silicon atom replacing a carbon atom in the diamond and a negatively-charged vacancy replacing a carbon atom adjacent to the nitrogen atom or silicon atom in the diamond; and
a halide atom.
Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
